Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Q3 2019 Earnings Presentation
18 slides from Trendlines's earnings presentation, Nov 7, 2019
Slide 1: The Trendlines Group Financial Highlights Q3 2019
The Trendlines Group Financial Highlights Q3 2019 Steve Rhodes Todd Dollinger Haim Brosh Chairman and CEO Chairman and CEO Chief Financial Officer 7 November 2019 SGX:42T OTCQX: TRNLY
Slide 2: Agenda
Agenda • Corporate highlights • Financial highlights • Post Q3 2019 developments 2
Slide 3: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 4: Corporate highlights
Corporate highlights
Slide 5: 12 years of portfolio value expansion
12 years of portfolio value expansion Note: Portfolio value does not reflect US$ millions 7 Singapore-based companies due to consolidation Portfolio value with exit proceeds 140 120 Portfolio value* (excluding consolidated subsidiaries) 100 Cumulative exit proceeds 80 60 40 20 0 31.12.08 31.12.09 31
Slide 6: Key financial developments Q3 2019
Key financial developments Q3 2019 30 September 2019 31 December 2018 Change Portfolio value US$ 94.6 million US$ 97.2 million - US$ 2.6 million Book value US$ 89.7 million US$ 86.4 million + US$ 3.3 million Current assets US$ 15 million US$ 11.8 million + US$ 3.2 million Q3 2019 Q3 2018 Change Tota
Slide 7: Key corporate developments Q3 2019
Key corporate developments Q3 2019 • Placement of US$8 million by Librae Holdings • Conditional investment commitments for Trendlines’ Singaporean Agrifood Fund • Announcement of Rights Issue • Trendlines welcomed its newest agtech Portfolio Company, EcoPhage Ltd., the second investment by the Bayer
Slide 8: Portfolio company achievements
Portfolio company achievements • MetoMotion Ltd. received US$1.5 million investment from a Netherlands-based strategic partner • ApiFix Ltd. received FDA approval for its MID-C System for treatment of scoliosis in adolescents • OrthoSpin Ltd. received FDA clearance for its robotic external fixation
Slide 9: Financial highlights
Financial highlights
Slide 10: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands, except share data 3 months ended 30 September 2019 2018 Income Loss from change in fair value of investments in Portfolio (1,931) 4,527 Companies Income from services to Portfolio Companies 1
Slide 11: Consolidated condensed report of income
Consolidated condensed report of income CONSOLIDATED STATEMENTS OF PROFIT OR LOSS U.S. dollars in thousands, except share data 3 months ended 30 September 2019 2018 Expenses Operating, general and administrative expenses 1,677 1,795 Marketing expenses 86 46 R&D expenses, net 276 163 Financial expens
Slide 12: Key value components
Key value components Change in portfolio value during Q32019 Balance sheet as at 30 September 2019 (US$ millions) 7.3 (9.9) 15 (3.3) (2.7) (13.0) (0.9) 97.2 94.6 89.7 Net portfolio Investments and Fair value Net portfolio Cash, short-term Fair value of Deferred Deferred tax** Payables & Total equity
Slide 13: Stock performance: Net Asset Value (NAV)
Stock performance: Net Asset Value (NAV) SGD Share USD ADR NAV per share/ADR* S$ 0.180 US$ 6.5 Price per share/ADR** S$ 0.091 US$ 3.35 % discount to NAV 49% 48% *As at 30 September 2019 **Market close as at 5 Nov 2019 13
Slide 14: Stock performance: Trendlines vs. Catalist Index trends
Stock performance: Trendlines vs. Catalist Index trends 12-month Trendlines vs Catalist Index Trend 350 11 300 9 250 7 FTSE ST Catalist Index Trendlines’ price per share 200 5 150 3 100 1 50 0 -1 1.11.18 3.12.18 2.1.19 1.2.19 1.3.19 1.4.19 2.5.19 3.6.19 1.7.19 1.8.19 2.9.19 1.10.19 1.11.19 FTSE ST C
Slide 15: Post Q3 2019 developments
Post Q3 2019 developments
Slide 16: Post Q3 2019 developments
Post Q3 2019 developments • Fidmi Medical Ltd. received FDA clearance for its low-profile enteral feeding device • Gordian Surgical Ltd. raised US$3 million for the commercialization of its access-closure system 16
Slide 17: Looking ahead: Trendlines Agrifood Fund
Looking ahead: Trendlines Agrifood Fund Agrifood tech-focused venture fund received commitments of up to US$22 million for first close Trendlines Group VP Nitza Kardish, PhD, • Will employ a blended early/late-stage investment strategy to: will be relocating to • Achieve early exits Singapore to • A
Slide 18: SGX: 42T OTCQX: TRNLY www.trendlines.com
SGX: 42T Steve Rhodes, Chairman & CEO OTCQX: TRNLY steve@trendlines.com Todd Dollinger, Chairman & CEO +972.72.260.7000 todd@trendlines.com www.trendlines.com Haim Brosh, Chief Financial Officer haim@trendlines.com 7 November 2019